Results 181 to 190 of about 12,374,157 (394)

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

open access: yesMolecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias   +12 more
wiley   +1 more source

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing

open access: yesMolecular Oncology, EarlyView.
Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef   +10 more
wiley   +1 more source

Cell receptor-independent infection by a neurotropic murine coronavirus. [PDF]

open access: yes, 1992
The cellular receptors for a coronavirus, mouse hepatitis virus (MHV), have been recently identified as one or more members of the carcinoembryonic antigen (CEA) family. The neurotropic JHM strain of MHV (MHV-JHM) possesses a highly fusogenic surface (S)
Buchmeier, MJ, Gallagher, TM, Perlman, S
core  

Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management

open access: yesMolecular Oncology, EarlyView.
DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez   +5 more
wiley   +1 more source

INDUCTION OF PROPHASE IN INTERPHASE NUCLEI BY FUSION WITH METAPHASE CELLS [PDF]

open access: bronze, 1972
Seiichi Matsui   +3 more
openalex   +1 more source

Small modifier, big decision: switching to SUMO mode adds weight to cancer stemness in mammary tumors

open access: yesMolecular Oncology, EarlyView.
Inhibition of protein SUMOylation has been shown to block tumorigenesis; however, the specific mechanisms by which SUMOylation controls the tumor‐initiating capacities remain elusive. Li et al. describe the role of Etv1 SUMOylation in cancer stem cells using mouse models of mammary gland tumorigenesis.
Veronika Yevdokimova, Yannick D. Benoit
wiley   +1 more source

Home - About - Disclaimer - Privacy